6 The phosphodiesterase-5 inhibitor sildenafil is licensed for PAH in FC I–IV from the USA and FC II–III in Europe. Endothelin receptor antagonists (ERAs) together with bosentan, sitaxentan and ambrisentan are oral therapies certified to be used in PAH. As no oral agent has proven superiority there remains debate concerning https://beauxpcoz.xzblogs.com/67574758/bosentan-secrets